CatalYm Presents Expanded Clinical and New Preclinical Data from
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
CatalYm today announced treatment of the first patients in a series of phase 2a cohorts targeting solid tumors, initiati…
First four dose escalation levels completed showing excellent tolerability for CTL-002 as monotherapy and in combination…
First HER2 directed therapy to show an improvement in overall survival for previously-treated metastatic gastric cancer…
9% of patients with HER2 mutant metastatic non-small cell lung cancer treated with ENHERTU achieved a tumor response Bre…
Results from the phase 2 DESTINY-CRC01 trial of Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZe…
SIRION Biotech provided successfully recombinant adenovirus containing the human BACH2 mRNA (GenBank: NM_021813) in a st…
Horizon Discovery™ (Horizon), a leading provider of research tools to support translational genomics and the development…
immatics biotechnologies GmbH, a clinicalstage biopharmaceutical company developing advanced therapeutic vaccines that a…
InteRNA Technologies B.V. and Cenix BioScience GmbH announce signing of a Research Agreement comprising functional scree…
Eine Studie in der neuen Ausgabe des "International Journal of Cancer" (IJC), Band 121 (5), zeigt, dass Alkoholentzug la…